YW2036

CAS No. 2131223-92-0

YW2036( —— )

Catalog No. M36036 CAS No. 2131223-92-0

YW2036 is an inhibitor of Wnt signaling pathway.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 149 In Stock
5MG 235 In Stock
10MG 353 In Stock
25MG 545 In Stock
50MG 766 In Stock
100MG 1008 In Stock
200MG 1341 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    YW2036
  • Note
    Research use only, not for human use.
  • Brief Description
    YW2036 is an inhibitor of Wnt signaling pathway.
  • Description
    YW2036 (compound 2a) is a potent Wnt/β-Catenin signaling pathway inhibitor with an IC50 value of 637 nM. YW2036 can be used in research of cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Wnt/Notch/Hedgehog
  • Target
    Wnt/beta/catenin
  • Recptor
    Wnt/beta-catenin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2131223-92-0
  • Formula Weight
    328.37
  • Molecular Formula
    C20H16N4O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC=1N(N=CC1C(NC2=NC3=C(C=C2)C=CC=C3)=O)C4=CC=CC=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yang W, et, al. Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation. J Med Chem. 2019 Dec 26;62(24):11151-11164. ?
molnova catalog
related products
  • Wnt pathway activato...

    Wnt pathway activator 2, with an IC50 of 13 nM, is a potent Wnt activator.

  • NRX-103094

    NRX-103094 is a potent enhancer of the interaction between β-catenin and the homologous E3 ligase SCFβ-TrCP, increasing the affinity of pSer33/Ser37 β-catenin for β-TrCP with an EC50 of 62 nM and a Kd of 0.6 nM.

  • Gadopentetate dimegl...

    Gadopentetate dimeglumine, an extracellular intravenous contrast agent, is used in combination with magnetic resonance imaging (MRI) to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on the MRI.